grey market glp 1 GLP-1 Agonists Report 2025-2033, By Product, Molecule, and Geo Study Finds GLP-1s Are Effectively

Patients initiating GLP-1 RA treatment (semaglutide, liraglutide, tirzepatide) were propensity scorematched (1:1) with RA controls not receiving GLP-1 RA therapy, balancing demographics, BMI categories, cardiovascular comorbidities, immunosuppressive therapies, and cardiometabolic medications

Incretin mimetics have established a massive market in diabetes and obesity, and have yet to reach their peak potential in these therapeutic areas

Nearly 1 in 3 prescribed medications are never filled, and individuals regularly adhere to only half of prescribed agents [268]

[2] More than 12% of U.S

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

Dehydration can worsen common side effects like nausea and fatigue